Overview
Cerevel Therapeutics was a clinical-stage neuroscience company developing selective receptor-targeted therapies for schizophrenia, Parkinson's disease, and epilepsy, best known for emraclidine, a muscarinic receptor agonist for schizophrenia. Cerevel was acquired by AbbVie in 2024 for approximately $8.7 billion.
More in Neuropharmaceuticals
Latest industry news
NIH-Backed Device Gives People With Paralysis a New Path to Communication
2026-10-14 · Research
ABILITY Neurotech Begins Clinical Testing of Its Brain-Computer Interface System
2026-10-13 · Research
Flourish Emerges From Stealth With Bezos and Google Ventures Backing to Decode the Nervous System
2026-10-12 · Funding
Cala Health Launches Next-Generation TAPS Therapy Wearable Nationwide for Tremor and Parkinson's Patients
2026-10-11 · Product
Company details
Category
💊 Neuropharmaceuticals
Location
Cambridge, USA
Funding
Acquired · AbbVie 2024
Website
www.cerevel.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →